ABCC4 Decreases docetaxel and not cabazitaxel efficacy in prostate cancer cells in vitro

This study aimed to investigate cabazitaxel efficacy in a model for docetaxel-resistant prostate cancer cells and to evaluate the involvement of ATP-cassette binding protein 4 (ABCC4) with regard to multidrug resistance. Docetaxel and cabazitaxel sensitivity was measured in PC3 and R3327-MATLyLu (ML...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Anticancer research 2013-02, Vol.33 (2), p.387-391
Hauptverfasser:	Oprea-Lager, Daniela E, Bijnsdorp, Irene V, VAN Moorselaar, Reindert J A, VAN DEN Eertwegh, Alfons J M, Hoekstra, Otto S, Geldof, Albert A
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Agents - pharmacology Blotting, Western Cell Line, Tumor Drug Resistance, Multiple Drug Resistance, Neoplasm - drug effects Drug Resistance, Neoplasm - physiology Humans In Vitro Techniques Male Multidrug Resistance-Associated Proteins - metabolism Prostatic Neoplasms - metabolism Taxoids - pharmacology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	This study aimed to investigate cabazitaxel efficacy in a model for docetaxel-resistant prostate cancer cells and to evaluate the involvement of ATP-cassette binding protein 4 (ABCC4) with regard to multidrug resistance. Docetaxel and cabazitaxel sensitivity was measured in PC3 and R3327-MATLyLu (MLL) cell lines, using the sulforhodamine B (SRB) assay. ABCC4 expression was examined by western blotting and its functional involvement in drug sensitivity by blocking with MK571 inhibitor. The docetaxel-resistant MLL cells (4.5-fold compared to cabazitaxel; p
ISSN:	1791-7530